MX2023015286A - Conjugado ligando-farmaco y uso de este. - Google Patents

Conjugado ligando-farmaco y uso de este.

Info

Publication number
MX2023015286A
MX2023015286A MX2023015286A MX2023015286A MX2023015286A MX 2023015286 A MX2023015286 A MX 2023015286A MX 2023015286 A MX2023015286 A MX 2023015286A MX 2023015286 A MX2023015286 A MX 2023015286A MX 2023015286 A MX2023015286 A MX 2023015286A
Authority
MX
Mexico
Prior art keywords
ligand
drug conjugate
conjugate
drug
Prior art date
Application number
MX2023015286A
Other languages
English (en)
Spanish (es)
Inventor
Gang Qian
Baohua Robert Huang
Zhongbo Wang
Wei Tan
Guitao Wang
Jun Shao
Shengfei MAO
Longjun Gu
Tingting Bu
Original Assignee
Coherent Biopharma Suzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherent Biopharma Suzhou Ltd filed Critical Coherent Biopharma Suzhou Ltd
Publication of MX2023015286A publication Critical patent/MX2023015286A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023015286A 2021-06-25 2022-06-24 Conjugado ligando-farmaco y uso de este. MX2023015286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021102377 2021-06-25
PCT/CN2022/101108 WO2022268202A1 (zh) 2021-06-25 2022-06-24 配体药物偶联物及其应用

Publications (1)

Publication Number Publication Date
MX2023015286A true MX2023015286A (es) 2024-04-03

Family

ID=84544230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015286A MX2023015286A (es) 2021-06-25 2022-06-24 Conjugado ligando-farmaco y uso de este.

Country Status (11)

Country Link
US (1) US20240358843A1 (https=)
EP (1) EP4360654A1 (https=)
JP (1) JP2024523524A (https=)
KR (1) KR20240025514A (https=)
CN (1) CN117693365A (https=)
AU (1) AU2022296571A1 (https=)
CA (1) CA3224741A1 (https=)
IL (1) IL309543A (https=)
MX (1) MX2023015286A (https=)
TW (1) TW202317199A (https=)
WO (1) WO2022268202A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
AU2022389555A1 (en) * 2021-11-17 2024-07-04 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate and use thereof
TW202428259A (zh) * 2022-12-23 2024-07-16 大陸商同宜醫藥（蘇州）有限公司 藥物組成物及其製備方法和用途
IL322887A (en) * 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof
WO2024222803A1 (zh) * 2023-04-26 2024-10-31 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311892B2 (en) * 2001-10-26 2007-12-25 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery
CN104411337A (zh) * 2012-07-09 2015-03-11 基因泰克公司 包含抗cd79b抗体的免疫偶联物
CN104784699B (zh) * 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
JP6772199B2 (ja) * 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
CN107412794B (zh) * 2017-04-17 2019-01-04 中国医学科学院北京协和医院 双靶点显像分子探针及其制备方法和应用
AU2020214507B2 (en) * 2019-01-30 2025-09-25 Coherent Biopharma (Suzhou), Limited Bi-ligand drug conjugate and use thereof

Also Published As

Publication number Publication date
IL309543A (en) 2024-02-01
JP2024523524A (ja) 2024-06-28
AU2022296571A1 (en) 2023-12-14
CA3224741A1 (en) 2022-12-29
KR20240025514A (ko) 2024-02-27
CN117693365A (zh) 2024-03-12
EP4360654A1 (en) 2024-05-01
WO2022268202A1 (zh) 2022-12-29
US20240358843A1 (en) 2024-10-31
TW202317199A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2023015286A (es) Conjugado ligando-farmaco y uso de este.
MX2025006132A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina
MX2023003448A (es) Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma.
EP4234560A3 (en) Antiviral prodrugs and nanoformulations thereof
MX2025010681A (es) Formulaciones transdermicas
ZA202307404B (en) Anti-met antibodies and uses thereof
MX2025011070A (es) Conjugados de anticuerpo-farmaco dll3 y usos de estos
MX2024013869A (es) Conjugados anticuerpo-farmaco 5t4 y usos de los mismos
AU201815763S (en) Quick connection coupler
PH12020552158A1 (en) Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
MX2025008789A (es) Variante de o-acilhomoserina sulfhidrilasa y su uso
SG10201806014TA (en) Feedback canceller and hearing aid
AU2022213743A9 (en) Conjugate and use thereof
PH12023550112A1 (en) Anti-notch2 antibodies and methods of use
MX2023008261A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
WO2019173382A8 (en) Gracilin a and congeners as immunosuppressive and neuroprotective agents
PH12022551172A1 (en) Anti-pcsk9 antibody and use thereof
MX2024003331A (es) Moleculas de union a d3 y usos de estas.
MX2021007200A (es) Complejo de zinc-arginina-cloruro.
MX2025002657A (es) Anticuerpo anti-ilt4 y uso farmaceutico del mismo
IL304281A (en) psma focused bracelet and its uses
ZA202300208B (en) Aqueous pickling compositions and their use
HK40105898A (en) Ligand-drug conjugate and use thereof
MX2024013189A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
CR20240504A (es) Antagonistas de at2r y usos de estos